Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
about
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's diseaseAn in situ measurement of extracellular cysteamine, homocysteine, and cysteine concentrations in organotypic hippocampal slice cultures by integration of electroosmotic sampling and microfluidic analysis.Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease.Diverse biological activities of the vascular non-inflammatory molecules - the Vanin pantetheinases.Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits.Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.Transglutaminase activation in neurodegenerative diseases.Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism.Transglutaminases and neurodegeneration.Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria.Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.Role of the Vnn1 pantetheinase in tissue tolerance to stress.Reciprocal Control of Thyroid Binding and the Pipecolate Pathway in the Brain.Serotonin as a putative scavenger of hypohalous acid in the brain.Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells.CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease.Cystamine and cysteamine as inhibitors of transglutaminase activity
P2860
Q24548047-A25B60D4-6501-4EC1-861D-CAC2B71EBC2BQ24618141-9499AE6F-9315-4B21-A473-0EA7682B8375Q30414243-A7E5B48D-BEB3-47F9-BE65-DFD6422D0024Q33912442-68C677B4-AABB-4D44-93A6-568C2BB6288AQ33944063-8256760B-31C2-4176-8307-7FFC6BCF018DQ35675063-918D04CA-FCB4-4D43-861E-F96874504AF4Q36024965-3CD5A913-A55B-47E9-B3EF-623DF491CA45Q36788489-F0B238EB-EA10-4089-B1BF-C69FB3210EBAQ37195530-E057C5AF-D492-41B2-8965-5AF70C044BC3Q37347572-2B228270-775D-44A5-9335-6D986DB8A6A2Q37352964-792F78C6-6818-452C-8AB2-CCF1B5EB0E42Q37365038-BB5427E4-60CA-4B99-A957-E317B8892BE5Q37365083-FB9683B1-D305-4D65-8430-3A1CE1BF3A37Q37857748-98CBA2D1-BDA1-42B5-B86E-0CB5602C8EE8Q37866383-67945511-C500-4094-87D5-EF9DDB36E141Q38238662-93CB2437-6BE3-4BD6-B1A9-253997C57FC4Q38925886-A3B0BB6F-EF1C-4661-888C-BD6262F8AF4AQ39854722-A54AA16D-2901-4968-A741-66DBEFE00959Q40290417-DD38DDDB-9E63-405F-8536-25CB17F9F0EEQ45298950-659CFFBC-B845-4AC1-A009-E4EB310A133BQ58763905-C8236B7B-CADD-4CE6-9239-1902B06BB099
P2860
Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Treatment of YAC128 mice and t ...... eatment of Huntington disease.
@en
Treatment of YAC128 mice and t ...... eatment of Huntington disease.
@nl
type
label
Treatment of YAC128 mice and t ...... eatment of Huntington disease.
@en
Treatment of YAC128 mice and t ...... eatment of Huntington disease.
@nl
prefLabel
Treatment of YAC128 mice and t ...... eatment of Huntington disease.
@en
Treatment of YAC128 mice and t ...... eatment of Huntington disease.
@nl
P2093
P2860
P50
P1476
Treatment of YAC128 mice and t ...... eatment of Huntington disease.
@en
P2093
Arthur J L Cooper
Howard T Thaler
Jeremy M Van Raamsdonk
John T Pinto
Thomas M Jeitner
P2860
P304
P356
10.1111/J.1471-4159.2005.03255.X
P407
P577
2005-06-30T00:00:00Z